Skip Navigation



JAC Advance Access published online on June 12, 2003
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkg294
© 2003 by The British Society for Antimicrobial Chemotherapy
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
52/1/43    most recent
dkg294v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Aubouy, A.
Right arrow Articles by Deloron, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aubouy, A.
Right arrow Articles by Deloron, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2003 Oxford University Press

Original article

DHFR and DHPS genotypes of Plasmodium falciparum isolates from Gabon correlate with in vitro activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy

Agnès Aubouy 1 , Sayeh Jafari 2 , Virginie Huart 2 , Florence Migot-Nabias 3 , Justice Mayombo 1 , Rémy Durand 2 , Mohamed Bakary 4 , Jacques Le Bras 2 , and Philippe Deloron 5 *

1 Centre International de Recherches Médicales de Franceville, Unité de Parasitologie Médicale, BP 769 Franceville, Gabon
2 Hôpital Bichat-Claude Bernard, Laboratoire de Parasitologie, 46 rue Henri Huchard, 75877 Paris, France
3 Centre International de Recherches Médicales de Franceville, Unité de Parasitologie Médicale, BP 769 Franceville, Gabon; Institut de Recherche pour le Développement (IRD), UR010, Mother and Child Health in the Tropics, BP1386, Dakar, Senegal
4 Bakoumba Hospital, BP52, Bakoumba, Gabon
5 Centre International de Recherches Médicales de Franceville, Unité de Parasitologie Médicale, BP 769 Franceville, Gabon; IRD UR010, Faculté de Pharmacie, Laboratoire de Parasitologie, 4 Avenue de l'Observatoire, 75006 Paris, France

* Corresponding author. E-mail: Philippe.Deloron{at}ird.fr.

Received 25 September 2002 ; revised 17 March 2003 ; accepted 22 April 2003

Abstract

Objectives: To assess the relationship between the presence of DHFR and DHPS mutations in Plasmodium falciparum, parasite in vitro resistance, and in vivo efficacy of sulfadoxine-pyrimethamine (SP) treatment.

Patients and methods: Measurement of SP treatment efficacy in malaria-infected children in Gabon was combined with in vitro tests of susceptibility to pyrimethamine and cycloguanil, and molecular genotyping at several DHFR and DHPS loci of parasites isolated before treatment. DHFR was studied at codons 108, 51, and 59, whereas DHPS gene was typed at positions 436, 437, 540 and 581.

Results: SP treatment was effective in 86% of children by day 28. Seventy-five percent of isolates were in vitro resistant to pyrimethamine and 65.5% to cycloguanil. No mutation was detected at codons 540 and 581 of the DHPS gene. Most isolates (71.8%) presented with the triple mutant DHFR genotype, whereas 64.3% combined at least three DHFR and one DHPS mutations. The increase in the number of DHFR mutations was associated with an increase in in vitro resistance to pyrimethamine and cycloguanil; three DHFR mutations conferred pyrimethamine and to a lesser extent cycloguanil resistance. Treatment failures only occurred with isolates presenting at least two DHFR mutations (S108N and C59R) and one DHPS mutation (S436A or A437G), but SP treatment of infections with such parasites gave treatment success in 82.0% of children.

Conclusions: DHFR mutations that lead to high-level in vitro resistance to pyrimethamine plus 1-2 DHPS mutations are not sufficient to induce in vivo failure of SP treatment in young children from Gabon.

Keywords: malaria, drug resistance, antifolates, molecular markers
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
H. TINTO, J. B. OUEDRAOGO, I. ZONGO, C. VAN OVERMEIR, E. VAN MARCK, T. R. GUIGUEMDE, and U. D'ALESSANDRO
SULFADOXINE-PYRIMETHAMINE EFFICACY AND SELECTION OF PLASMODIUM FALCIPARUM DHFR MUTATIONS IN BURKINA FASO BEFORE ITS INTRODUCTION AS INTERMITTENT PREVENTIVE TREATMENT FOR PREGNANT WOMEN
Am J Trop Med Hyg, April 1, 2007; 76(4): 608 - 613.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
D. MENARD, D. DJALLE, F. YAPOU, A. MANIRAKIZA, and A. TALARMIN
FREQUENCY DISTRIBUTION OF ANTIMALARIAL DRUG-RESISTANT ALLELES AMONG ISOLATES OF PLASMODIUM FALCIPARUM IN BANGUI, CENTRAL AFRICAN REPUBLIC
Am J Trop Med Hyg, February 1, 2006; 74(2): 205 - 210.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
G. DORSEY, C. DOKOMAJILAR, M. KIGGUNDU, S. G. STAEDKE, M. R. KAMYA, and P. J. ROSENTHAL
PRINCIPAL ROLE OF DIHYDROPTEROATE SYNTHASE MUTATIONS IN MEDIATING RESISTANCE TO SULFADOXINE-PYRIMETHAMINE IN SINGLE-DRUG AND COMBINATION THERAPY OF UNCOMPLICATED MALARIA IN UGANDA
Am J Trop Med Hyg, December 1, 2004; 71(6): 758 - 763.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. L. Gatton, L. B Martin, and Q. Cheng
Evolution of Resistance to Sulfadoxine-Pyrimethamine in Plasmodium falciparum
Antimicrob. Agents Chemother., June 1, 2004; 48(6): 2116 - 2123.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.